News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Under Armour, Inc. (NYSE:UAA)'s long-running turnaround just got tougher. On August 7, the athletic clothing manufacturer forecasted a sharper annual revenue decline, and investors responded by sending shares down as much as 9% in early trade, showing the market's lack of patience for a …
Sharemaestro market context Price below Trend Line 52 weeks -2.1%Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong second-quarter 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increase signals management's confidence in XDEMVY's commercial trajectory, though the company still faces risks associated …
Ascendis Pharma A/S reported strong Q2 results, with revenues beating expectations by 2.8% and statutory profit exceeding forecasts by 104%. Analysts have subsequently upgraded their EPS estimates for 2026, though the consensus price target remains unchanged at US$310. The company is expected to continue …
SCS Capital Management LLC acquired 612,850 shares of Agios Pharmaceuticals (NASDAQ:AGIO) during the second quarter, valued at approximately $22.7 million. The biopharmaceutical company reported a quarterly loss per share of $1.69, missing estimates, but exceeded revenue expectations with $44.75 million. Analyst sentiment for AGIO …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the …
Sharemaestro market context New activity signal 52 weeks +11.9% · Next-week setup negative 4.6%Kinsale Capital Group Inc. significantly increased its stake in CarMax, Inc. by 18.8% in Q2 2026, bringing its total holdings to 174,637 shares valued at $9.24 million. Despite recent insider purchases and a "Strong Buy" upgrade from Zacks, CarMax carries an average "Hold" rating …
USA Financial Formulas has acquired a new stake in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 1,457 shares valued at approximately $1.13 million, making it their 27th-largest portfolio holding. Institutional investors collectively own 83.31% of Regeneron, with several major firms significantly increasing their positions. The company recently …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated …
5 Insightful Analyst Questions From Under Armour's Q2 Earnings Call Under Armour's second quarter results were met with a significant negative market reaction, as revenue fell short of Wall Street expectations and declined year over year. Management attributed the shortfall to softer consumer demand, …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …
Avalon Trust Co recently acquired 177,782 shares of HA Sustainable Infrastructure Capital, Inc. (NYSE:HASI) for approximately $6.94 million, representing about 0.14% of the company. Other institutional investors also adjusted their holdings in the real estate investment trust, which specializes in financing climate change solutions. …
Assenagon Asset Management S.A. significantly reduced its stake in Alarm.com Holdings, Inc. (ALRM) by 78% in the second quarter of 2026, selling 54,969 shares and retaining 15,473 shares valued at approximately $723,000. Despite this, Alarm.com exceeded quarterly earnings expectations with $0.77 EPS against a …
Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …
ABN AMRO Bank N.V. has invested $20.21 million in Sprouts Farmers Market (SFM), acquiring a 0.26% stake. The investment comes amidst mixed analyst sentiment for SFM, with some near-term earnings estimates lowered due to softer comparable sales and margin pressure, despite the company slightly …
Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …
Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …
Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …
This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …
Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …
Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …
This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Under Armour (UAA) is back in focus after updating investors on both near term and full year expectations. The company paired a new …
Eton Pharmaceuticals (NASDAQ: ETON) saw its shares rise significantly in pre-market trading after reporting stronger-than-expected second-quarter financial results and providing an optimistic revenue guidance for FY26. The company exceeded analyst consensus estimates for both earnings per share and sales. The article also lists other …
Teva Pharmaceutical Industries (TEVA) has initiated a phase 2b trial for its anti IL-15 antibody TEV-'408 for nonsegmental vitiligo, following promising phase 1b results. This development, coupled with a significant 1-year share price return of 105.88%, has renewed investor interest. While the stock is …
Sharemaestro market context Trend signal active 52 weeks +71.0%BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that invest in Regeneron Pharmaceuticals, Inc. (RGO) stocks. The list, sorted by market value, details each fund's symbol, market value, weight of RGO stock, issuer, management style, focus, expense ratio, assets under management …
Search by ticker symbol or company name and select a result to open its chart.